Loading...
MDXH
XNAS
Market cap10mUSD
Nov 20, Last price  
0.11USD
1D
-8.52%
1Q
-85.55%
IPO
-99.11%
Name

MDxHealth SA

Chart & performance

D1W1MN
XNAS:MDXH chart
P/E
—
P/S
0.09
EPS
—
Vol. 1Y
158.09%
Shs. 5Y
43.16%
Rev. 5Y
42.34%
Div Yld LY
—
Div Yld TTM
—
Revenues
108m
+19.80%
3,657,1683,850,5834,209,7053,650,6393,372,7883,482,5994,918,4017,554,00011,479,00017,467,00029,867,00040,508,00028,338,00011,785,00018,460,00022,239,00037,054,00070,193,00090,049,000107,875,000
Net income
-34m
L-11.95%
0000000-16,175,000-15,256,000-14,473,000-13,174,000-12,288,000-32,450,000-43,100,000-28,662,000-29,002,000-44,044,000-43,100,000-38,069,000-33,519,000
CFO
-10m
L-43.78%
0000000-14,105,000-18,513,000-14,394,000-16,585,000-10,489,000-28,543,000-22,289,000-20,244,000-22,548,000-34,118,000-21,497,000-18,530,000-10,417,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

MDxHealth SA is a commercial-stage precision diagnostics firm delivering specialized urologic solutions across the globe. Its international footprint includes the United States, various European nations such as the Netherlands, Belgium, Spain, Poland, Italy, and the wider European Union. The company's innovative genomic testing portfolio for prostate cancer comprises SelectMDx, a non-invasive urine test, and ConfirmMDx, an epigenetic diagnostic tool. These advanced offerings enable medical professionals to precisely identify clinically significant prostate cancer, thereby minimizing reliance on invasive procedures and their associated risks. Established in 2003, with its headquarters in Herstal, Belgium, the entity was formerly known as OncoMethylome Sciences SA until its renaming to MDxHealth SA in October 2010.

Key people

Michael McGarrity
Chief Executive Officer, Director · since 2019
Joseph Sollee
Executive Vice President, Chief Compliance Officer, General Counsel · since 2017
Christopher Thibodeau
Executive Vice President & U.S. Chief Operations Officer · since 2017
John Bellano
Chief Commercial Officer · since 2019
Director · since 2025
Sanford Siegel
Director · since 2024
Rudi Marien
Non-Executive Director · since 2011
Ruth Devenyns
Non-Executive Independent Director · since 2011
Walter Narajowski
Non-Executive Independent Director · since 2015
Mark Shaffar
Non-Executive Independent Chairman of the Board · since 2016
IPO date
Jun 26, 2006
Employees
252
Domiciled in
BE
Incorporated in
BE
Headquarters & legal address
Rue d'Abhooz 31
Herstal, WLG 4040
BE

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT